Discovery of potential new markers of invasive prostate cancer
The prostate is a sexual secretory gland with both internal and external secretory functions, located between the bladder and the urogenital ridge. The prostate secretes prostatic fluid, which is the main component of semen. It also secretes a hormone called "prostaglandin".
The prostate is an important organ of the male, but with the pollution of the environment, people's life pressure is gradually increasing, and more and more prostate cancer patients. Prostate cancer ranks first in the incidence of cancer in Europe and the United States. In recent years, morbidity and mortality have increased significantly.
A study published in the Cell Reports by a team led by Dr. Esther Baena of the British Institute of Cancer Research at the Institute of Cancer Research in the United Kingdom has shown that a mouse prostate cancer cell carrying a marker is resistant to hormonal therapy. They believed that this may also be related to the early development of human prostate cancer.
The researchers found that 20 percent of men with prostate cancer had a higher risk of cancer metastasis after surgery. And Baena believed this may be associated with a group of prostate cancer cells that are tolerant of available therapies.
Cancer cells resistant to treatment are not specific to prostate cancer and are not a new phenomenon. These cells are often the cause of cancer recurrence. Although these resistant cells are known to be present in prostate cancer, they lack markers that can separate them.
Dr. Baena thought that one of the biggest challenges facing prostate cancer so far is how to stratify patients.
First, the team identified normal prostate cells that survived treatment and then found a new marker on the surface of these resistant cells called LY6D
The researchers then studied cancer mouse model markers and discovered that markers with mice developed more aggressive tumors.
Based on these promising results, they also began looking for any link between LY6D and aggressive prostate cancer in patient samples. Through the genetic database, they found that high levels of LY6D were associated with lower overall survival rates in patients with prostate cancer.
LY6D has been found on other cells in the body, including one found in the immune system. Similar markers have also been found in other tumor types such as breast and colon cancer.
Other members of the LYD family are involved in cells that divide and interact with the immune system or promote the spread of cancer. However, LY6D is not well characterized, so we are currently studying it further.
What they knew is that the cells that produce LY6D are more resistant to the common hormone therapy for prostate cancer, called androgen deprivation.
This will allow doctors to identify invasive tumors with cells that express this marker at an early stage. It will also help us isolate them and understand why they are unique and resistant.
They hoped that one day their work help identify men who may not be able to fully cope with current treatments. When men are diagnosed with prostate cancer, they can be sure that they have LY6D-labeled cells, and doctors can intervene this in advance.
They plan to learn more about the mysterious LY6D molecule, including what it does and whether it can be used to target these aggressive prostate cancer cells.
Cite this article
CUSABIO team. Discovery of potential new markers of invasive prostate cancer. https://www.cusabio.com/c-20882.html